Latest news with #Enchant
Yahoo
3 days ago
- Business
- Yahoo
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO, June 10, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. "While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials," said Tom Miller, PhD, Iambic's co-founder and CEO. "Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas." Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. "Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals." The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@
Business Wire
3 days ago
- Business
- Business Wire
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. 'While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials,' said Tom Miller, PhD, Iambic's co-founder and CEO. 'Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas.' Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. 'Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals.' The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at
CNBC
3 days ago
- Business
- CNBC
26. Iambic Therapeutics
Founders: Tom Miller (CEO), Fred ManbyLaunched: 2020Headquarters: San Diego, CaliforniaFunding: $220 millionValuation: N/AKey Technologies: Artificial intelligence, cloud computing, deep neural networks/deep learning, generative AI, machine learning, robotics, quantum computingIndustry: BiotechPrevious appearances on Disruptor 50 list: 0 It can take 10-15 years for today's biopharmaceutical companies to bring new drugs all the way through discovery and clinical trial. San Diego-based Iambic Therapeutics' AI-driven platform can accelerate the pace of drug discovery and development, enabling drug development in just a few years. The company has novel medications in its pipeline to treat breast cancer and other HER2 cancers, and recently formed a research collaboration with pharmaceutical giant Lundbeck for a small molecule therapeutic to treat migraines. By predicting how its new molecules will interact with human systems, Iambic's technology can also reduce the need for clinical trials. The company was originally called Entos, and was founded when CEO Thomas Miller, a theoretical chemist and professor at California Institute of Technology, teamed up with longtime collaborator Fred Manby. In its first iteration, the company worked on making better chemical predictions across many industries and worked with companies including Toyota and Procter & Gamble. But the founders saw applications for their work in what's called small molecule drug discovery. Small molecule drugs, often synthesized chemically, target specific proteins or cellular pathways. Iambic's platform for drug discovery is called Enchant. The company says it provides high-confidence predictions in data-poor situations, such as early-stage and clinical-stage drug programs. "(Cancer) is an area of huge need," Miller told an interviewer for the California Institute of Technology in 2022. "It's an incredibly fast, quickly advancing disease. Many people are afflicted by it. There's many varieties of it. It is the combination of those things that means that if you have the ability to design a new drug, there's a way to … have a relatively fast timescale to advance that to the point where it's in human trials." Rather than selling its drug-discovery services and software to pharmaceutical companies, Iambic has focused on producing its own drugs. "Instead of running around, trying to convince people that this software is so great, and they should buy it, you can actually just use it and execute with it, and actually make better molecules. Then those molecules can stand on their own two feet," Miller said. In 2024, Iambic completed a B round of funding, with investors including OrbiMed, Nvidia and Sequoia Capital, and announced a collaboration with Nvidia, which has been teaming up as a venture investor with many startups across sectors using AI, including, for example, agtech Disruptor Carbon Robotics. Iambic also moved into a new headquarters in San Diego last year and took its headcount to about 100, enabling the company to run experiments on thousands of newly discovered molecules each week. It also announced an update to NeuralPLexer, which predicts protein-ligand structures, and published data in Nature Machine Intelligence showing that NeuralPLexer outperformed AlphaFold, the Nobel Prize in Chemistry winner developed by Google's DeepMind. Iambic also hired its first CFO, Michael Secora, who previously worked at publicly held Recursion.
Yahoo
28-05-2025
- Business
- Yahoo
Iambic Therapeutics to Participate in June Investor Conferences
SAN DIEGO, May 28, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following June investor conferences: Jefferies Global Healthcare Conference - June 3 - 5, 2025 UBS Spring Biotech Conference - June 24, 2025 About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
Business Mayor
22-05-2025
- Business
- Business Mayor
Enchant launches zero-equity accelerator for gaming and AI startups
Enchant is launching a new zero-equity accelerator for gaming and AI startups, with applications now open for its three-month program. The accelerator is dedicated to early-stage teams at the crossroads of gaming and artificial intelligence. Founded by veterans of Sony, Supercell, EA, Ubisoft and Playrix, the fully remote program gives founders hands-on product sprints, weekly one-on-one sessions with industry leaders and direct access to a global investor network — while letting every startup keep 100 percent of its cap-table. Enchant backs companies building games, gaming-industry tools, AI products and Web3 experiences. By stripping away office requirements and equity grabs, the accelerator concentrates on rapid product iteration, real-world traction and warm introductions to publishers, VCs and strategic partners, said Eugenii Unegovskiy, cofounder of Enchant, in an interview with GamesBeat. Enchant is taking applications for its zero-equity accelerator. The program is an intensive 12-week track that begins the day a team is accepted. Founders apply whenever they're ready; there is no need to wait for fixed cohorts. From day one, each company follows a milestone roadmap that includes product deep-dives, go-to-market workshops and Demo-Day preparation. 'Founders shouldn't have to wait for a calendar slot,' said Unegovskiy. 'Acceptance triggers day-one sprints, live play-tests and build reviews shoulder-to-shoulder with veterans from triple-A studios. It's real co-building, not classroom mentoring, and it means products hit the market in weeks, not months.' 'Zero-equity is a strong benefit, with an even bigger advantage being a clean cap table that helps early gaming and AI teams close future rounds faster,' added Aakash Parameswaran, CEO of Fable Fox, a former Game Designer at Electronic Arts and an expert in Enchant, in a statement. 'From refining core loops to designing live-service economies, we work in the trenches so founders stay player-first and ship games investors can trust.' Read More Call of Duty: Modern Warfare 2 Enchant is taking flat fees for its work. Keeping the cap-table clean at the earliest stage helps founders retain control and stay more attractive for future Seed and Series A rounds, when dilution stakes are far larger. It also lets Enchant operate purely on the startup's success, aligning incentives around product wins and fundraising milestones. Applications are reviewed on a rolling basis, and accepted teams can start immediately. Unegovskiy said that while running demo days for game startups at Subscrible, he realized something crucial: most early-stage founders don't fail because the product is weak — they fail because the business around it isn't ready. No go-to-market, no monetization strategy, no clear idea how much money they need — or why. 'That's why I teamed up with folks from Supercell, Ubisoft, Sony, EA, King, Xsolla, and Oracle — many of whom I'm sure you know or have crossed paths with — along with the creators of Tetris, Angry Birds, and Cut the Rope, to launch Enchant, a new kind of accelerator for gaming and AI startups,' Unegovskiy said. Without cohorts or equity, the company will provide focused support that helps founders move forward. 'We help with pitch training, fundraising prep, GTM and monetization strategy, grant and UA support, legal and marketing guidance — plus access to tools, credits, and partner services worth over $500,000 (cloud credits, analytics, dev tools, etc.),' Unegovskiy said. 'It's a simple model: small monthly fee + a success fee if we help a team raise or grow — no early dilution.' The team includes Tim Horton, an experienced gaming executive with 16+ years in leadership, business development, and partnerships within the global gaming industry. Horton helps optimize operations, drive growth, and deliver high-quality projects in mobile gaming, triple-A art, console porting, and game development. Sutton Trout specializes in leadership/strategic partnerships/business development/goal attainment and revenue. He is an action-oriented leader with 20 years of experiences in games and entertainment. He has worked at Supercell, Sony and WB Games. And he helped with complex projects and major launches like Hogwarts Legacy. Also on the team is Andrey Feinberg (Kuznetsov), former CIO at GDEV and Nexters. He has more than 10 years of experience in gaming, tech, and internet industries. He helped closed 40+ deals worth over $800 million, and he is now an independent advisor focused on fundraising, M&A, and strategy for gaming and interactive entertainment companies. Unegovskiy is one of the experts, as he is a six-time founder with experience in game development and AI. Other experts include Amir Shaked, Igor Diev, Jun Qian, Oded Lavie, Martin Hoszowski, Kevin Beardslee, Yosef Warburg, Wes Harris, Elvis Fernandes, Han Lee, Faisal Nazir, Tim Gerritsen, Hovav Shoshan, Igor Bazhanov, Cipto Adiguno, Casey Dickinson, Rosario Basilotta, Aakash Parameswaran, Mariam Japaridze and Eugene Volikov. Enchant expert Aakash Parameswaran, CEO of Fable Fox. By not taking a stake in the company, Unegovskiy said the company focuses on working side-by-side with founders to improve everything from pitch to revenue strategy. It takes a flat monthly fee, plus a success fee if it helps a team raise money or grow. The fee is typically 5% to 10% of the raised amount or a share of revenue growth. 'We also reserve the right to invest in future rounds on founder-friendly terms — aligned with long-term support, not short-term ownership,' said Unegovskiy. He also said mentors and advisserss are similiarly aligned to the startup's success. The focus of games and AI at Enchant. The company just opened applications and are starting to see a diverse mix of early-stage founders — from game studios to AI-tool builders, across multiple regions. A significant share of interest is coming from projects working at the intersection of gaming and AI — blending creative ambition with scalable infrastructure. 'We're seeing strong indicators that the next wave of gaming startups will be deeply technical, globally minded, and looking for business-first support without early dilution,' Unegovskiy said.
